tasimelteon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4820	609799-22-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tasimelteon hetlioz VEC-162 BMS-214778	an agonist at melatonin MT1 and MT2 receptors, these receptors are thought to be involved in the control of circadian rhythms Molecular weight: 245.32 Formula: C15H19NO2 CLOGP: 1.89 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 38.33 ALOGS: -3.81 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tasimelteon
hetlioz
VEC-162
BMS-214778

an agonist at melatonin MT1 and MT2 receptors, these receptors are thought to be involved in the control of circadian rhythms

Molecular weight: 245.32
Formula: C15H19NO2
CLOGP: 1.89
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 38.33
ALOGS: -3.81
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.33 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.04 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.75 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 31, 2014	FDA	VANDA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Insomnia	349.49	43.12	167	2213	174698	50428046
Middle insomnia	338.54	43.12	81	2299	9840	50592904
Drug ineffective	324.66	43.12	279	2101	819054	49783690
Product dose omission issue	239.70	43.12	132	2248	183706	50419038
Incorrect product administration duration	212.10	43.12	55	2325	9220	50593524
Nightmare	173.55	43.12	53	2327	16033	50586711
Abnormal dreams	173.34	43.12	47	2333	9330	50593414
Somnolence	137.36	43.12	87	2293	154898	50447846
Initial insomnia	129.87	43.12	33	2347	5082	50597662
Therapeutic product effect delayed	97.97	43.12	22	2358	1999	50600745
Therapeutic product effect decreased	83.57	43.12	61	2319	135989	50466755
Poor quality sleep	69.53	43.12	27	2353	16619	50586125
Therapeutic product effect variable	48.13	43.12	11	2369	1079	50601665
Sleep disorder	47.59	43.12	31	2349	57252	50545492
Hypersomnia	47.28	43.12	20	2360	15294	50587450
Headache	43.91	43.12	82	2298	506453	50096291

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	468.84	61.78	275	1464	362895	29209893
Middle insomnia	404.66	61.78	88	1651	5620	29567168
Insomnia	268.53	61.78	121	1618	88640	29484148
Incorrect product administration duration	234.64	61.78	53	1686	3988	29568800
Nightmare	206.75	61.78	59	1680	11358	29561430
Product dose omission issue	158.22	61.78	87	1652	96296	29476492
Abnormal dreams	149.01	61.78	41	1698	6879	29565909
Somnolence	135.57	61.78	78	1661	93877	29478911
Therapeutic product effect decreased	113.81	61.78	48	1691	29403	29543385
Initial insomnia	106.20	61.78	26	1713	2749	29570039
Feeling abnormal	62.07	61.78	39	1700	54406	29518382

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	458.42	52.54	319	2184	839928	63656301
Middle insomnia	411.12	52.54	96	2407	12781	64483448
Incorrect product administration duration	371.55	52.54	84	2419	9674	64486555
Insomnia	329.06	52.54	157	2346	197679	64298550
Nightmare	266.11	52.54	75	2428	20918	64475311
Product dose omission issue	241.81	52.54	127	2376	194620	64301609
Abnormal dreams	211.61	52.54	54	2449	10302	64485927
Somnolence	153.20	52.54	96	2407	203549	64292680
Initial insomnia	122.08	52.54	31	2472	5773	64490456
Therapeutic product effect decreased	106.10	52.54	62	2441	115289	64380940
Therapeutic product effect delayed	75.76	52.54	18	2485	2541	64493688
Poor quality sleep	71.16	52.54	27	2476	18924	64477305
Headache	62.97	52.54	89	2414	529378	63966851

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05CH03	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Melatonin receptor agonists
FDA MoA	N0000000250	Melatonin Receptor Agonists
FDA EPC	N0000175743	Melatonin Receptor Agonist
CHEBI has role	CHEBI:79046	melatonin receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-24 hour sleep-wake cycle	indication	230496009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.05	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	5856529	Dec. 9, 2022	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	5856529	Dec. 9, 2022	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	5856529	Dec. 9, 2022	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10149829	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10149829	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10449176	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10610510	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10610510	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10945988	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10980770	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENISSYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10980770	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	11285129	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	11285129	Jan. 25, 2033	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9060995	Jan. 25, 2033	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9539234	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9539234	Jan. 25, 2033	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9549913	Jan. 25, 2033	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9855241	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	RE46604	Jan. 25, 2033	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	10149829	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	10610510	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	10980770	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENISSYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	11285129	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	9539234	Jan. 25, 2033	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9730910	May 17, 2034	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	9730910	May 17, 2034	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	9730910	May 17, 2034	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10610511	Oct. 10, 2034	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10610511	Oct. 10, 2034	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	11141400	Oct. 10, 2034	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	11141400	Oct. 10, 2034	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	10610511	Oct. 10, 2034	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	11141400	Oct. 10, 2034	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10376487	July 27, 2035	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10376487	July 27, 2035	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	10376487	July 27, 2035	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	10179119	Aug. 29, 2035	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	10179119	Aug. 29, 2035	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	Dec. 1, 2023	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	Dec. 1, 2023	NEW PRODUCT
20MG	HETLIOZ	VANDA PHARMS INC	N205677	Jan. 31, 2014	RX	CAPSULE	ORAL	Dec. 1, 2027	THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
4MG/ML	HETLIOZ LQ	VANDA PHARMS INC	N214517	Dec. 1, 2020	RX	SUSPENSION	ORAL	Dec. 1, 2027	FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Melatonin receptor type 1A	GPCR	P48039	MTR1A_HUMAN	AGONIST	Ki	9.45		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Melatonin receptor type 1B	GPCR	P49286	MTR1B_HUMAN	AGONIST	Ki	9.80		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
D09388	KEGG_DRUG
4033173	VUID
N0000190488	NUI
4033173	VANDF
CHEBI:79042	CHEBI
CHEMBL2103822	ChEMBL_ID
C478745	MESH_SUPPLEMENTAL_RECORD_UI
7393	IUPHAR_LIGAND_ID
8985	INN_ID
DB09071	DRUGBANK_ID
SHS4PU80D9	UNII
10220503	PUBCHEM_CID
1490468	RXNORM
211275	MMSL
30166	MMSL
d08240	MMSL
015295	NDDF
702394009	SNOMEDCT_US
704468000	SNOMEDCT_US
C1313052	UMLSCUI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Hetlioz	HUMAN PRESCRIPTION DRUG LABEL	1	43068-220	CAPSULE	20 mg	ORAL	NDA	34 sections
HetliozLQ	HUMAN PRESCRIPTION DRUG LABEL	1	43068-304	SUSPENSION	4 mg	ORAL	NDA	34 sections